Genomic Medicine Market; by Component (Gene Medicine, Platforms & Services) by Application (Oncology, Cardiology, Pediatrics, Endocrinology, Respiratory Medicine, Rare Genetic Disorders, Infectious Diseases, Diabetes, Others), by End Users (Hospitals & Clinics, Academic Institutes & Research Centers, Others); by Region (U.S., Canada, Mexico, Rest of North America, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America ) — Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027
Market Overview/Industry Trends
Scientists and doctors have been studying genes and hereditary conditions for several years. Currently, it is possible for someone to have a genetic test for various types of medical conditions. A blood sample is taken and minutely studied for abnormal chromosomes but as so much information is stored on the deoxyribonucleic acid (DNA), scientists only tend to look for particular disorders. According to the Aetna Inc., genomic medicine is the study of genes and their interaction with health. Genomics investigates the intricate biological details of an individual and the use of these for effective diagnosis and customized treatment. Moreover, genomics denotes the study of someone's whole genetic makeup. It's about how they relate and respond with each other and is linked with conditions that have a wider range of causes such as heart disease, diabetes, asthma, and cancer. Genomic medicine is used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis, and for tracking of epidemics of infectious diseases. Thereby, it is expected to support the genomic medicine market growth over the forecast period.
Results from genomic studies help researchers, physicians, and patients to better understand the diseases and the underlying mechanisms. It encourages decision-making based on evidence and hence assists to improve the customized treatment regime. Genomic medicine is a type of precision medicine in which genomics, epigenomics, and other related data are used to precisely help in the individual disease diagnosis. Genomic medicine can suspect if someone is susceptible to certain diseases such as stroke, heart disease, and cancer. It might be possible that they are likely to have high cholesterol levels or they might be suffering problems with their veins. If the patients have this knowledge, they can cope up with this risk through medicines, medical intervention, or by making positive variations in their lifestyle. Hence, it is assisting in driving the growth of the genomic medicine market.
Moreover, genomic medicine is used for prenatal tests that is done during pregnancy and hence drive the genomic medicine market growth. It assists the parents to make well-versed choices and plans for the forthcoming. Genomic medicine evaluates if there is a family history of serious genetic disorders and then it can tell potential parents whether or not they are a carrier and if they can transfer it to their children. It can also inform someone if they are likely to develop the inherited condition later in life, even if they don't yet have any symptoms.
Various technologies such as cell therapy, gene therapy, gene editing, and genome regulations are provided by Editas Medicine and Sangamo Therapeutics, which is expected to assist in the genomic medicine market growth over the study period. Developments in the scientific fields of cell therapy and gene therapy have facilitated the success of gene editing which has led to an increase in the growth of a new class of genomic medicines. Genome regulation incorporates all sides of gene expression from the biochemical alterations of deoxyribonucleic acid to the physical preparation of chromosomes and the activity of the transcription machinery. For instance, Sangamo Therapeutics regulates the gene expression by using zinc finger proteins (ZFPs) which is a class of transcription factors that identify and bind to specific sequences of deoxyribonucleic acid code, allowing a cell to distinguish the targeted gene from thousands of others. The family of zinc finger proteins is one of the most common genes in the human genome.
In terms of revenue, the global genomic medicine market was valued at US$ 4,840.0 Bn in 2018 and is expected to reach US$ 11,785.5 Bn by 2027 growing at a CAGR of 10.5% over the forecast period. The study analyzes the market in terms of revenue across all the major regions, which has been further bifurcated into countries.
Genomic Medicine Market Revenue & Forecast, (US$ Billion), 2015–2027
Component Outlook:
Based on component, the genomic medicine market has been bifurcated into gene medicine and platforms & services. Among all, platforms & services is expected to witness the favorable market growth during the forecast period. Companies are developing platforms to ease the diagnosis for doctors as wells as for patients. For example, Genome Medical, Inc. has developed a platform called telehealth in which individuals and healthcare providers can connect with genetic experts with the assistance of the cloud-based platform, telehealth. With the help of telehealth, individuals and healthcare providers can receive counseling on the health issues they might face as well as they can gain advice on how to implement a healthier lifestyle based on their genetic makeup.
Therapeutic Area Outlook:
The genomic medicine market is gaining momentum with its growing applications in various therapeutic areas such as oncology, cardiology, pediatrics, endocrinology, respiratory medicine, rare genetic disorders, and infectious diseases, among others. The oncology segment will hold the major share in the genomic medicine market owing to increasing rate of cancer cases across the world. For example, according to the National Cancer Institute (NCI), in the U.S., there has been 439.2 per 100,000 men and women cancer cases registered per year between 2011 and 2015. Out of this, the number of deaths from cancer is 163.5 per 100,000 men and women registered per year between 2011 and 2015.
End-user Outlook:
Based on the end-user, the genomic medicine market has been classified into hospitals & clinics, academic institutes & research centers, and others. The hospitals & clinics segment held the largest market share in 2018. The genetic sequencing was not used to effectively treat rare and chronic diseases by most of healthcare organizations a couple of years ago due to high cost and inefficient technology; but with new and more cost-effective technologies developing every day, the world of genomic medicine is gaining high momentum. At present, genomic medicine is used by hospitals and bringing with it non-invasive technology that is used to cure diseases including brain cancer and cholera. For instance, Rady Children’s Hospital Institute for Genomic Medicine in San Diego, United States is using genomic medicine and technology to display, diagnose and heal children in its intensive care unit.
On the other hand, the academic institutes & research centers segment will exhibit the fastest genomic medicine market growth during the forecast period from 2019 to 2027. Academic institutes & research centers are working on the genetic data to find the cure for various diseases such as cancer, diabetes, among others. For example, National Human Genome Research Institute has a separate division for genomic medicine in which the division frame the strategies, directs and enables multi-disciplinary research to recognize genetic contributions to human health and improve diagnosis, cure and prevention from diseases through research grants, research training grants, and contracts.
Regional Outlook:
Due to the presence of a large number of academics as well as research institutions working on genomic medicine in the U.S., North America is expected to lead the global genomic medicine market in terms of value during the forecast period. It is also anticipated that the presence of several universities providing educational programs coupled with incentives for genomic medicine science research in North America and Europe will have a positive impact on the regional markets.
Competitive Landscape
The report provides both, qualitative and quantitative research about the genomic medicine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The major players present in the market include Abomics Ltd, Cerecor, Inc. (Aevi Genomic Medicine, Inc.), Congenica Ltd, DEEP GENOMICS, Editas Medicine, EUROESPES, Genome Medical, Inc., Helix OpCo LLC, Parexel International Corporation, Sangamo Therapeutics, and uniQure N.V. These market participants are adopting various growth strategies such as new product launches, mergers and acquisitions, partnerships and collaborations, among others to gain a competitive advantage. For instance, in February 2020, Sangamo Therapeutics, Inc. collaborated with Biogen Inc. for the development of gene regulation therapies for Parkinson’s, Alzheimer’s, neuromuscular, and other neurological diseases.
Genomic Medicine Market:
- By Component
- Gene Medicine
- Platforms & Services
- By Therapeutic Area
- Oncology
- Cardiology
- Endocrinology
- Respiratory Diseases
- Rare Genetic Diseases
- Infectious Diseases
- Diabetes
- Others
- By End-User
- Hospitals & Clinics
- Academic Institutes & Research Centers
- Others
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Genomic Medicine Market
6. Market
Synopsis: Genomic Medicine Market
7. Genomic
Medicine Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Genomic Medicine Market
7.4. Macro-Economic
and Micro-Economic Indicators: Genomic Medicine Market
7.5. Porter’s
Five Force Analysis
8. Global
Genomic Medicine Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Genomic Medicine Market Revenue (US$ Mn)
8.2. Global
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
8.2.1. Gene
Medicine
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Platforms
and Services
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Component
9. Global
Genomic Medicine Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
9.2.1. Oncology
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Cardiology
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Endocrinology
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Respiratory
Diseases
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Rare
Genetic Diseases
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2018
9.2.5.3. Market
Forecast, 2019 – 2027
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.2.6. Infectious
Diseases
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2013 – 2018
9.2.6.3. Market
Forecast, 2019 – 2027
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2013 – 2018
9.2.6.5.1.2. Market
Forecast, 2019 – 2027
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2013 – 2018
9.2.6.5.2.2. Market
Forecast, 2019 – 2027
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2013 – 2018
9.2.6.5.3.2. Market
Forecast, 2019 – 2027
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2013 – 2018
9.2.6.5.4.2. Market
Forecast, 2019 – 2027
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2013 – 2018
9.2.6.5.5.2. Market
Forecast, 2019 – 2027
9.2.7. Diabetes
9.2.7.1. Definition
9.2.7.2. Market
Estimation and Penetration, 2013 – 2018
9.2.7.3. Market
Forecast, 2019 – 2027
9.2.7.4. Compound
Annual Growth Rate (CAGR)
9.2.7.5. Regional
Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market
Estimation, 2013 – 2018
9.2.7.5.1.2. Market
Forecast, 2019 – 2027
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2013 – 2018
9.2.7.5.2.2. Market
Forecast, 2019 – 2027
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market
Estimation, 2013 – 2018
9.2.7.5.3.2. Market
Forecast, 2019 – 2027
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market
Estimation, 2013 – 2018
9.2.7.5.4.2. Market
Forecast, 2019 – 2027
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market
Estimation, 2013 – 2018
9.2.7.5.5.2. Market
Forecast, 2019 – 2027
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market
Estimation and Penetration, 2013 – 2018
9.2.8.3. Market
Forecast, 2019 – 2027
9.2.8.4. Compound
Annual Growth Rate (CAGR)
9.2.8.5. Regional
Bifurcation
9.2.8.5.1. North
America
9.2.8.5.1.1. Market
Estimation, 2013 – 2018
9.2.8.5.1.2. Market
Forecast, 2019 – 2027
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2013 – 2018
9.2.8.5.2.2. Market
Forecast, 2019 – 2027
9.2.8.5.3. Asia
Pacific
9.2.8.5.3.1. Market
Estimation, 2013 – 2018
9.2.8.5.3.2. Market
Forecast, 2019 – 2027
9.2.8.5.4. Middle
East and Africa
9.2.8.5.4.1. Market
Estimation, 2013 – 2018
9.2.8.5.4.2. Market
Forecast, 2019 – 2027
9.2.8.5.5. Latin
America
9.2.8.5.5.1. Market
Estimation, 2013 – 2018
9.2.8.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapeutic Area
10. Global
Genomic Medicine Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
10.2.1. Hospitals
and Clinics
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Academic
Institutes and Research Centers
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
End-User
11. North
America Genomic Medicine Market Analysis and Forecasts, 2019 - 2027
11.1. Overview
11.1.1. North
America Genomic Medicine Market Revenue (US$ Mn)
11.2. North
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
11.2.1. Gene
Medicine
11.2.2. Platforms
and Services
11.3. North
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
11.3.1. Oncology
11.3.2. Cardiology
11.3.3. Endocrinology
11.3.4. Respiratory
Diseases
11.3.5. Rare
Genetic Diseases
11.3.6. Infectious
Diseases
11.3.7. Diabetes
11.3.8. Others
11.4. North
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
11.4.1. Hospitals
and Clinics
11.4.2. Academic
Institutes and Research Centers
11.4.3. Others
11.5. North
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
11.5.1.1.1. Gene
Medicine
11.5.1.1.2. Platforms
and Services
11.5.1.2. U.S
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.1.2.1. Oncology
11.5.1.2.2. Cardiology
11.5.1.2.3. Endocrinology
11.5.1.2.4. Respiratory
Diseases
11.5.1.2.5. Rare
Genetic Diseases
11.5.1.2.6. Infectious
Diseases
11.5.1.2.7. Diabetes
11.5.1.2.8. Others
11.5.1.3. U.S
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.1.3.1. Hospitals
and Clinics
11.5.1.3.2. Academic
Institutes and Research Centers
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
11.5.2.1.1. Gene
Medicine
11.5.2.1.2. Platforms
and Services
11.5.2.2. Canada
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.2.2.1. Oncology
11.5.2.2.2. Cardiology
11.5.2.2.3. Endocrinology
11.5.2.2.4. Respiratory
Diseases
11.5.2.2.5. Rare
Genetic Diseases
11.5.2.2.6. Infectious
Diseases
11.5.2.2.7. Diabetes
11.5.2.2.8. Others
11.5.2.3. Canada
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.2.3.1. Hospitals
and Clinics
11.5.2.3.2. Academic
Institutes and Research Centers
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
11.5.3.1.1. Gene
Medicine
11.5.3.1.2. Platforms
and Services
11.5.3.2. Mexico
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.3.2.1. Oncology
11.5.3.2.2. Cardiology
11.5.3.2.3. Endocrinology
11.5.3.2.4. Respiratory
Diseases
11.5.3.2.5. Rare
Genetic Diseases
11.5.3.2.6. Infectious
Diseases
11.5.3.2.7. Diabetes
11.5.3.2.8. Others
11.5.3.3. Mexico
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.3.3.1. Hospitals
and Clinics
11.5.3.3.2. Academic
Institutes and Research Centers
11.5.3.3.3. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Component
11.5.4.1.1. Gene
Medicine
11.5.4.1.2. Platforms
and Services
11.5.4.2. Rest
of North America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
11.5.4.2.1. Oncology
11.5.4.2.2. Cardiology
11.5.4.2.3. Endocrinology
11.5.4.2.4. Respiratory
Diseases
11.5.4.2.5. Rare
Genetic Diseases
11.5.4.2.6. Infectious
Diseases
11.5.4.2.7. Diabetes
11.5.4.2.8. Others
11.5.4.3. Rest
of North America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
End-User
11.5.4.3.1. Hospitals
and Clinics
11.5.4.3.2. Academic
Institutes and Research Centers
11.5.4.3.3. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Component
11.6.3. By
Therapeutic Area
11.6.4. By
End-User
12. Europe
Genomic Medicine Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Europe
Genomic Medicine Market Revenue (US$ Mn)
12.2. Europe
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.2.1. Gene
Medicine
12.2.2. Platforms
and Services
12.3. Europe
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.3.1. Oncology
12.3.2. Cardiology
12.3.3. Endocrinology
12.3.4. Respiratory
Diseases
12.3.5. Rare
Genetic Diseases
12.3.6. Infectious
Diseases
12.3.7. Diabetes
12.3.8. Others
12.4. Europe
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.4.1. Hospitals
and Clinics
12.4.2. Academic
Institutes and Research Centers
12.4.3. Others
12.5. Europe
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.1.1.1. Gene
Medicine
12.5.1.1.2. Platforms
and Services
12.5.1.2. France
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.1.2.1. Oncology
12.5.1.2.2. Cardiology
12.5.1.2.3. Endocrinology
12.5.1.2.4. Respiratory
Diseases
12.5.1.2.5. Rare
Genetic Diseases
12.5.1.2.6. Infectious
Diseases
12.5.1.2.7. Diabetes
12.5.1.2.8. Others
12.5.1.3. France
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.1.3.1. Hospitals
and Clinics
12.5.1.3.2. Academic
Institutes and Research Centers
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The
UK Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.2.1.1. Gene
Medicine
12.5.2.1.2. Platforms
and Services
12.5.2.2. The
UK Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.2.2.1. Oncology
12.5.2.2.2. Cardiology
12.5.2.2.3. Endocrinology
12.5.2.2.4. Respiratory
Diseases
12.5.2.2.5. Rare
Genetic Diseases
12.5.2.2.6. Infectious
Diseases
12.5.2.2.7. Diabetes
12.5.2.2.8. Others
12.5.2.3. The
UK Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.2.3.1. Hospitals
and Clinics
12.5.2.3.2. Academic
Institutes and Research Centers
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.3.1.1. Gene
Medicine
12.5.3.1.2. Platforms
and Services
12.5.3.2. Spain
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.3.2.1. Oncology
12.5.3.2.2. Cardiology
12.5.3.2.3. Endocrinology
12.5.3.2.4. Respiratory
Diseases
12.5.3.2.5. Rare
Genetic Diseases
12.5.3.2.6. Infectious
Diseases
12.5.3.2.7. Diabetes
12.5.3.2.8. Others
12.5.3.3. Spain
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.3.3.1. Hospitals
and Clinics
12.5.3.3.2. Academic
Institutes and Research Centers
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.4.1.1. Gene
Medicine
12.5.4.1.2. Platforms
and Services
12.5.4.2. Germany
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.4.2.1. Oncology
12.5.4.2.2. Cardiology
12.5.4.2.3. Endocrinology
12.5.4.2.4. Respiratory
Diseases
12.5.4.2.5. Rare
Genetic Diseases
12.5.4.2.6. Infectious
Diseases
12.5.4.2.7. Diabetes
12.5.4.2.8. Others
12.5.4.3. Germany
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.4.3.1. Hospitals
and Clinics
12.5.4.3.2. Academic
Institutes and Research Centers
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.5.1.1. Gene
Medicine
12.5.5.1.2. Platforms
and Services
12.5.5.2. Italy
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.5.2.1. Oncology
12.5.5.2.2. Cardiology
12.5.5.2.3. Endocrinology
12.5.5.2.4. Respiratory
Diseases
12.5.5.2.5. Rare
Genetic Diseases
12.5.5.2.6. Infectious
Diseases
12.5.5.2.7. Diabetes
12.5.5.2.8. Others
12.5.5.3. Italy
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.5.3.1. Hospitals
and Clinics
12.5.5.3.2. Academic
Institutes and Research Centers
12.5.5.3.3. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.6.1.1. Gene
Medicine
12.5.6.1.2. Platforms
and Services
12.5.6.2. Nordic
Countries Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
12.5.6.2.1. Oncology
12.5.6.2.2. Cardiology
12.5.6.2.3. Endocrinology
12.5.6.2.4. Respiratory
Diseases
12.5.6.2.5. Rare
Genetic Diseases
12.5.6.2.6. Infectious
Diseases
12.5.6.2.7. Diabetes
12.5.6.2.8. Others
12.5.6.3. Nordic
Countries Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.6.3.1. Hospitals
and Clinics
12.5.6.3.2. Academic
Institutes and Research Centers
12.5.6.3.3. Others
12.5.6.4. Nordic
Countries Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.7.1.1. Gene
Medicine
12.5.7.1.2. Platforms
and Services
12.5.7.2. Benelux
Union Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
12.5.7.2.1. Oncology
12.5.7.2.2. Cardiology
12.5.7.2.3. Endocrinology
12.5.7.2.4. Respiratory
Diseases
12.5.7.2.5. Rare
Genetic Diseases
12.5.7.2.6. Infectious
Diseases
12.5.7.2.7. Diabetes
12.5.7.2.8. Others
12.5.7.3. Benelux
Union Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.7.3.1. Hospitals
and Clinics
12.5.7.3.2. Academic
Institutes and Research Centers
12.5.7.3.3. Others
12.5.7.4. Benelux
Union Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
12.5.8.1.1. Gene
Medicine
12.5.8.1.2. Platforms
and Services
12.5.8.2. Rest
of Europe Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
12.5.8.2.1. Oncology
12.5.8.2.2. Cardiology
12.5.8.2.3. Endocrinology
12.5.8.2.4. Respiratory
Diseases
12.5.8.2.5. Rare
Genetic Diseases
12.5.8.2.6. Infectious
Diseases
12.5.8.2.7. Diabetes
12.5.8.2.8. Others
12.5.8.3. Rest
of Europe Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.8.3.1. Hospitals
and Clinics
12.5.8.3.2. Academic
Institutes and Research Centers
12.5.8.3.3. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Component
12.6.3. By
Therapeutic Area
12.6.4. By
End-User
13. Asia
Pacific Genomic Medicine Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Asia
Pacific Genomic Medicine Market Revenue (US$ Mn)
13.2. Asia
Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.2.1. Gene
Medicine
13.2.2. Platforms
and Services
13.3. Asia
Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
13.3.1. Oncology
13.3.2. Cardiology
13.3.3. Endocrinology
13.3.4. Respiratory
Diseases
13.3.5. Rare
Genetic Diseases
13.3.6. Infectious
Diseases
13.3.7. Diabetes
13.3.8. Others
13.4. Asia
Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.4.1. Hospitals
and Clinics
13.4.2. Academic
Institutes and Research Centers
13.4.3. Others
13.5. Asia
Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.1.1.1. Gene
Medicine
13.5.1.1.2. Platforms
and Services
13.5.1.2. China
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.1.2.1. Oncology
13.5.1.2.2. Cardiology
13.5.1.2.3. Endocrinology
13.5.1.2.4. Respiratory
Diseases
13.5.1.2.5. Rare
Genetic Diseases
13.5.1.2.6. Infectious
Diseases
13.5.1.2.7. Diabetes
13.5.1.2.8. Others
13.5.1.3. China
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.1.3.1. Hospitals
and Clinics
13.5.1.3.2. Academic
Institutes and Research Centers
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.2.1.1. Gene
Medicine
13.5.2.1.2. Platforms
and Services
13.5.2.2. Japan
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.2.2.1. Oncology
13.5.2.2.2. Cardiology
13.5.2.2.3. Endocrinology
13.5.2.2.4. Respiratory
Diseases
13.5.2.2.5. Rare
Genetic Diseases
13.5.2.2.6. Infectious
Diseases
13.5.2.2.7. Diabetes
13.5.2.2.8. Others
13.5.2.3. Japan
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.2.3.1. Hospitals
and Clinics
13.5.2.3.2. Academic
Institutes and Research Centers
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.3.1.1. Gene
Medicine
13.5.3.1.2. Platforms
and Services
13.5.3.2. India
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.3.2.1. Oncology
13.5.3.2.2. Cardiology
13.5.3.2.3. Endocrinology
13.5.3.2.4. Respiratory
Diseases
13.5.3.2.5. Rare
Genetic Diseases
13.5.3.2.6. Infectious
Diseases
13.5.3.2.7. Diabetes
13.5.3.2.8. Others
13.5.3.3. India
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.3.3.1. Hospitals
and Clinics
13.5.3.3.2. Academic
Institutes and Research Centers
13.5.3.3.3. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.4.1.1. Gene
Medicine
13.5.4.1.2. Platforms
and Services
13.5.4.2. New
Zealand Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
13.5.4.2.1. Oncology
13.5.4.2.2. Cardiology
13.5.4.2.3. Endocrinology
13.5.4.2.4. Respiratory
Diseases
13.5.4.2.5. Rare
Genetic Diseases
13.5.4.2.6. Infectious
Diseases
13.5.4.2.7. Diabetes
13.5.4.2.8. Others
13.5.4.3. New
Zealand Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.4.3.1. Hospitals
and Clinics
13.5.4.3.2. Academic
Institutes and Research Centers
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.5.1.1. Gene
Medicine
13.5.5.1.2. Platforms
and Services
13.5.5.2. Australia
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.5.2.1. Oncology
13.5.5.2.2. Cardiology
13.5.5.2.3. Endocrinology
13.5.5.2.4. Respiratory
Diseases
13.5.5.2.5. Rare
Genetic Diseases
13.5.5.2.6. Infectious
Diseases
13.5.5.2.7. Diabetes
13.5.5.2.8. Others
13.5.5.3. Australia
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.5.3.1. Hospitals
and Clinics
13.5.5.3.2. Academic
Institutes and Research Centers
13.5.5.3.3. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.6.1.1. Gene
Medicine
13.5.6.1.2. Platforms
and Services
13.5.6.2. South
Korea Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
13.5.6.2.1. Oncology
13.5.6.2.2. Cardiology
13.5.6.2.3. Endocrinology
13.5.6.2.4. Respiratory
Diseases
13.5.6.2.5. Rare
Genetic Diseases
13.5.6.2.6. Infectious
Diseases
13.5.6.2.7. Diabetes
13.5.6.2.8. Others
13.5.6.3. South
Korea Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.6.3.1. Hospitals
and Clinics
13.5.6.3.2. Academic
Institutes and Research Centers
13.5.6.3.3. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
13.5.7.1.1. Gene
Medicine
13.5.7.1.2. Platforms
and Services
13.5.7.2. Southeast
Asia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
13.5.7.2.1. Oncology
13.5.7.2.2. Cardiology
13.5.7.2.3. Endocrinology
13.5.7.2.4. Respiratory
Diseases
13.5.7.2.5. Rare
Genetic Diseases
13.5.7.2.6. Infectious
Diseases
13.5.7.2.7. Diabetes
13.5.7.2.8. Others
13.5.7.3. Southeast
Asia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.7.3.1. Hospitals
and Clinics
13.5.7.3.2. Academic
Institutes and Research Centers
13.5.7.3.3. Others
13.5.7.4. Southeast
Asia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Component
13.5.8.1.1. Gene
Medicine
13.5.8.1.2. Platforms
and Services
13.5.8.2. Rest
of Asia Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
13.5.8.2.1. Oncology
13.5.8.2.2. Cardiology
13.5.8.2.3. Endocrinology
13.5.8.2.4. Respiratory
Diseases
13.5.8.2.5. Rare
Genetic Diseases
13.5.8.2.6. Infectious
Diseases
13.5.8.2.7. Diabetes
13.5.8.2.8. Others
13.5.8.3. Rest
of Asia Pacific Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
End-User
13.5.8.3.1. Hospitals
and Clinics
13.5.8.3.2. Academic
Institutes and Research Centers
13.5.8.3.3. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Component
13.6.3. By
Therapeutic Area
13.6.4. By
End-User
14. Middle
East and Africa Genomic Medicine Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Genomic Medicine Market Revenue (US$ Mn)
14.2. Middle
East and Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Component
14.2.1. Gene
Medicine
14.2.2. Platforms
and Services
14.3. Middle
East and Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
14.3.1. Oncology
14.3.2. Cardiology
14.3.3. Endocrinology
14.3.4. Respiratory
Diseases
14.3.5. Rare
Genetic Diseases
14.3.6. Infectious
Diseases
14.3.7. Diabetes
14.3.8. Others
14.4. Middle
East and Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
End-User
14.4.1. Hospitals
and Clinics
14.4.2. Academic
Institutes and Research Centers
14.4.3. Others
14.5. Middle
East and Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
14.5.1.1.1. Gene
Medicine
14.5.1.1.2. Platforms
and Services
14.5.1.2. Saudi
Arabia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
14.5.1.2.1. Oncology
14.5.1.2.2. Cardiology
14.5.1.2.3. Endocrinology
14.5.1.2.4. Respiratory
Diseases
14.5.1.2.5. Rare
Genetic Diseases
14.5.1.2.6. Infectious
Diseases
14.5.1.2.7. Diabetes
14.5.1.2.8. Others
14.5.1.3. Saudi
Arabia Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.1.3.1. Hospitals
and Clinics
14.5.1.3.2. Academic
Institutes and Research Centers
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
14.5.2.1.1. Gene
Medicine
14.5.2.1.2. Platforms
and Services
14.5.2.2. UAE
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.2.2.1. Oncology
14.5.2.2.2. Cardiology
14.5.2.2.3. Endocrinology
14.5.2.2.4. Respiratory
Diseases
14.5.2.2.5. Rare
Genetic Diseases
14.5.2.2.6. Infectious
Diseases
14.5.2.2.7. Diabetes
14.5.2.2.8. Others
14.5.2.3. UAE
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.2.3.1. Hospitals
and Clinics
14.5.2.3.2. Academic
Institutes and Research Centers
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
14.5.3.1.1. Gene
Medicine
14.5.3.1.2. Platforms
and Services
14.5.3.2. Egypt
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.3.2.1. Oncology
14.5.3.2.2. Cardiology
14.5.3.2.3. Endocrinology
14.5.3.2.4. Respiratory
Diseases
14.5.3.2.5. Rare
Genetic Diseases
14.5.3.2.6. Infectious
Diseases
14.5.3.2.7. Diabetes
14.5.3.2.8. Others
14.5.3.3. Egypt
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.3.3.1. Hospitals
and Clinics
14.5.3.3.2. Academic
Institutes and Research Centers
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
14.5.4.1.1. Gene
Medicine
14.5.4.1.2. Platforms
and Services
14.5.4.2. Kuwait
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.4.2.1. Oncology
14.5.4.2.2. Cardiology
14.5.4.2.3. Endocrinology
14.5.4.2.4. Respiratory
Diseases
14.5.4.2.5. Rare
Genetic Diseases
14.5.4.2.6. Infectious
Diseases
14.5.4.2.7. Diabetes
14.5.4.2.8. Others
14.5.4.3. Kuwait
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.4.3.1. Hospitals
and Clinics
14.5.4.3.2. Academic
Institutes and Research Centers
14.5.4.3.3. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
14.5.5.1.1. Gene
Medicine
14.5.5.1.2. Platforms
and Services
14.5.5.2. South
Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
14.5.5.2.1. Oncology
14.5.5.2.2. Cardiology
14.5.5.2.3. Endocrinology
14.5.5.2.4. Respiratory
Diseases
14.5.5.2.5. Rare
Genetic Diseases
14.5.5.2.6. Infectious
Diseases
14.5.5.2.7. Diabetes
14.5.5.2.8. Others
14.5.5.3. South
Africa Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.5.3.1. Hospitals
and Clinics
14.5.5.3.2. Academic
Institutes and Research Centers
14.5.5.3.3. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Genomic Medicine Market Revenue (US$ Mn) and
Forecasts, By Component
14.5.6.1.1. Gene
Medicine
14.5.6.1.2. Platforms
and Services
14.5.6.2. Rest
of Middle East & Africa Genomic Medicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Area
14.5.6.2.1. Oncology
14.5.6.2.2. Cardiology
14.5.6.2.3. Endocrinology
14.5.6.2.4. Respiratory
Diseases
14.5.6.2.5. Rare
Genetic Diseases
14.5.6.2.6. Infectious
Diseases
14.5.6.2.7. Diabetes
14.5.6.2.8. Others
14.5.6.3. Rest
of Middle East & Africa Genomic Medicine Market Revenue (US$ Mn) and
Forecasts, By End-User
14.5.6.3.1. Hospitals
and Clinics
14.5.6.3.2. Academic
Institutes and Research Centers
14.5.6.3.3. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Component
14.6.3. By
Therapeutic Area
14.6.4. By
End-User
15. Latin
America Genomic Medicine Market Analysis and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Latin
America Genomic Medicine Market Revenue (US$ Mn)
15.2. Latin
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
15.2.1. Gene
Medicine
15.2.2. Platforms
and Services
15.3. Latin
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
15.3.1. Oncology
15.3.2. Cardiology
15.3.3. Endocrinology
15.3.4. Respiratory
Diseases
15.3.5. Rare Genetic
Diseases
15.3.6. Infectious
Diseases
15.3.7. Diabetes
15.3.8. Others
15.4. Latin
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
15.4.1. Hospitals
and Clinics
15.4.2. Academic
Institutes and Research Centers
15.4.3. Others
15.5. Latin
America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
15.5.1.1.1. Gene
Medicine
15.5.1.1.2. Platforms
and Services
15.5.1.2. Brazil
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.1.2.1. Oncology
15.5.1.2.2. Cardiology
15.5.1.2.3. Endocrinology
15.5.1.2.4. Respiratory
Diseases
15.5.1.2.5. Rare
Genetic Diseases
15.5.1.2.6. Infectious
Diseases
15.5.1.2.7. Diabetes
15.5.1.2.8. Others
15.5.1.3. Brazil
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1.3.1. Hospitals
and Clinics
15.5.1.3.2. Academic
Institutes and Research Centers
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Component
15.5.2.1.1. Gene
Medicine
15.5.2.1.2. Platforms
and Services
15.5.2.2. Argentina
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.2.2.1. Oncology
15.5.2.2.2. Cardiology
15.5.2.2.3. Endocrinology
15.5.2.2.4. Respiratory
Diseases
15.5.2.2.5. Rare
Genetic Diseases
15.5.2.2.6. Infectious
Diseases
15.5.2.2.7. Diabetes
15.5.2.2.8. Others
15.5.2.3. Argentina
Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.2.3.1. Hospitals
and Clinics
15.5.2.3.2. Academic
Institutes and Research Centers
15.5.2.3.3. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Component
15.5.3.1.1. Gene
Medicine
15.5.3.1.2. Platforms
and Services
15.5.3.2. Rest
of Latin America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
15.5.3.2.1. Oncology
15.5.3.2.2. Cardiology
15.5.3.2.3. Endocrinology
15.5.3.2.4. Respiratory
Diseases
15.5.3.2.5. Rare
Genetic Diseases
15.5.3.2.6. Infectious
Diseases
15.5.3.2.7. Diabetes
15.5.3.2.8. Others
15.5.3.3. Rest
of Latin America Genomic Medicine Market Revenue (US$ Mn) and Forecasts, By
End-User
15.5.3.3.1. Hospitals
and Clinics
15.5.3.3.2. Academic
Institutes and Research Centers
15.5.3.3.3. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By Country
15.6.2. By
Component
15.6.3. By
Therapeutic Area
15.6.4. By
End-User
16. Competitive
Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player
Profiles
17.1. Abomics
Ltd
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Cerecor,
Inc. (Aevi Genomic Medicine, Inc.)
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT Analysis
17.2.7. Business
Strategies
17.3. Congenica
Ltd
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. DEEP
GENOMICS
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Editas
Medicine
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. EUROESPES
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Genome
Medical, Inc.
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Helix
OpCo LLC
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Parexel
International Corporation
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Sangamo
Therapeutics
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. uniQure
N.V.
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Other
Market Participants
18. Key
Findings
Note: This ToC is tentative and can
be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.